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Abstract
Background. Although high-performance liquid chromatography (HPLC) is the method of choice for blood sirolimus
determination, the microparticle enzyme immunoassay (MEIA) run on the IMx† analyser is widely used in therapeutic
monitoring of this immunosuppressant agent. The aim of our study was to evaluate the possible determination of sirolimus
using the fluorescence polarization immunoassay (FPIA) commercialized for everolimus quantification.
Methods. Sirolimus concentrations were determined in whole-blood samples from liver and kidney transplant recipients
using the Innofluor† Certican† FPIA (Seradyn Inc.) run on a TDx† analyser (Abbott Laboratories), Sirolimus MEIA run
on an IMx† analyser (Abbott Laboratories), and HPLC (UV detection) methods.
Results. The Innofluor† FPIA has a similar cross-reactivity with everolimus and sirolimus, and the within- and between-run
coefficients of variation obtained for sirolimus determination were 2.7% 13.3%. In analysing different blood samples from
liver and kidney transplant patients the linear regressions obtained were: FPIA 1.12 HPLC 0.43 (n 104, r 0.874),
MEIA 1.14 HPLC (n 146, r 0.892), and FPIA 1.00 MEIA 0.29 (n 106, r 0.941). Better correlation coefficients
were obtained between the methods in the liver transplant samples (r]0.900) than in the kidney transplant samples (r]
0.849). No significant effect was found for sirolimus clearance or the blood hematocrit on the relationship between the
results produced by both immunoassays and HPLC.
Conclusion. The Innofluor† FPIA is a valid alternative with an analogous performance to the MEIA for the therapeutic
monitoring of sirolimus.
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Sirolimus (Rapamune†, Wyeth-Ayerst, Princeton,
USA) is a macrolide antibiotic with potent antipro-
liferation and immunosuppressant properties. The
drug has a narrow therapeutic index, and a poor
correlation between the doses and blood concentra-
tions, resulting from the variability in metabolism
and P glycoprotein drug transport mechanisms (1).
Clinical studies have shown significant correlations
between trough sirolimus concentrations and the
area under the concentration-time curve, with a
strong relationship between drug toxicity and trough
concentrations above 15 mg/L (2,3). Consequently,
therapeutic monitoring of sirolimus is necessary in
order to minimize adverse side-effects and to ensure
effective immunosuppression. As 94% of sirolimus is
found within erythrocytes, EDTA-anticoagulated
whole blood is the appropriate matrix for its
quantification (3).
The recommended and still most commonly
used method for blood sirolimus determination is
high-performance liquid chromatography (HPLC),
using tandem mass spectrometric detection or ultra-
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DOI: 10.1080/03009730802608254violet detection. However, simpler techniques for
sirolimus management have been developed, such as
the microparticle enzyme immunoassay (MEIA) or
the cloned enzyme donor immunoassay (CEDIA).
Sirolimus measurements using HPLC have tended
to be focused in larger transplant centres, although
sirolimus immunoassays may be performed by local
laboratories providing a more rapid turn-around
time of results (4). The MEIA assay has been
extensively evaluated, and in accordance with the
majority of authors is a viable alternative to HPLC-
based methods for routine sirolimus monitoring (4 
12); however, due to the sirolimus-metabolite cross-
reactivity with the antibody, users must consider the
implications of the variable MEIA overestimation
when interpreting the results (13). With respect to
the sirolimus CEDIA, few studies on its analytical
performance have been published, and they reached
discordant conclusions (14,15).
A fluorescence polarization immunoassay (FPIA)
is marketed by Seradyn Inc. for the determination of
everolimus (Certican†, Novartis Pharma AG, Basel,
Switzerland), an immunosuppressive derivative of
sirolimus with a 2-hydroxyethyl chain at position 40
(16). As sirolimus and everolimus molecules are
highly similar, and an analogous cross-reactivity
against the antibody may be expected, the present
study was aimed at evaluating whether the ever-
olimus FPIA assay could be applied to the determi-
nation of sirolimus. The study includes correlations
with the MEIA and HPLC/UV.
Material and methods
The sirolimus levels were determined in whole-
blood samples from different adult liver and kidney
transplant recipients, both in the immediate post-
transplant period and the maintenance period. In
most cases, sirolimus was administered in combina-
tion with low-dose calcineurin inhibitors: tacrolimus
in liver recipients and tacrolimus or cyclosporin in
kidney recipients. The samples were taken in
Vacutainer† tubes containing EDTA prior to the
next dose of sirolimus, and at least after a 10-day
period without any modification of the dosage. As a
result, the blood sirolimus concentrations corre-
spond to the steady-state trough levels. The study
was carried out according to the good practice rules
for investigation in humans of the Conselleria de
Sanidade (Regional Ministry of Health) of the Xunta
de Galicia, Santiago de Compostela, Spain.
Sirolimus determination using the Innofluor†
Certican† FPIA (Seradyn Inc., Indianapolis, USA)
was carried out according to the manufacturer’s
specifications for everolimus determination, using a
TDx† analyser (Abbott Laboratories, Abbott Park,
USA) and calibrated with Innofluor† Certican†
calibrators (Seradyn Inc.). The determinations using
the Sirolimus MEIA (Abbott Laboratories) were
carried out according to the manufacturer’s instruc-
tions in an IMx† analyser (Abbott Laboratories).
The blood concentrations of sirolimus were also
determined by HPLC with UV detection in an
Agilent 1200 series system, using a slightly modified
version of the method of French et al. (17), in which
after 1-chlorobutane extraction the supernatant was
dried using a SPD1010 SpeedVac† system (Thermo
Savant). The IMx† Sirolimus controls (Abbott
Laboratories) were used for the intralaboratory daily
quality control. Sirolimus clearance (CL) was esti-
mated using the equation (18): CL (F)(Dose/ )/
Css, where F corresponds to the sirolimus bioavail-
ability (approximately 0.15), is the dosing interval,
and Css the whole-blood sirolimus concentration
determined by HPLC. As trough rather than average
sirolimus concentrations were used, reported CL
represents overestimates of the actual values. The
serum levels of albumin, bilirubin, creatinine, and
urea were determined in an Advia 2400 Chemistry
System. The glomerular filtration rate (GFR) was
estimated from age, sex, race, and serum creatinine,
albumin, and urea concentrations, using the 6-
variable Modification of Diet in Renal Disease
formula (19).
Statistical analysis was carried out using the
StatGraphics Plus (v. 5.0) package, and the Sha-
piro-Wilks method was used to check the distribu-
tion of data. Pearson’s correlation coefficient was
used when the data had a Gaussian distribution;
otherwise, Spearman’s correlation coefficient was
used. The regression analysis was made using the
Passing-Bablok non-parametric method, and conse-
quently the ma68 value was used as standard error of
the estimate for the evaluation of dispersion data.
The results obtained with the different methods were
also compared using Eksborg difference plots (20).
In accordance with previously established criteria
(21,22), and considering a therapeutic range for
sirolimus of 5 15 mg/L (1,3), the clinically accepta-
ble deviation error is51.3 mg/L, with an acceptable
value50.6 m/L for the standard error of the esti-
mate, and a clinically acceptable coefficient of
variation56.3%. Similarly, in accordance with the
consensus criteria for the validation of analytical
methods used for the quantitative determination of
drugs and their metabolites in biological samples
(23,24), the accepted level for accuracy is a deviation
error of no more than 15% from the nominal value,
and for imprecision a variation coefficient no higher
56 L. Bouzas et al.than 15% (for levels above the limit of quantifica-
tion). The results were expressed as mean9SD
(median).
Results
Our MEIA and HPLC assays fulfilled the acceptance
criteria of the Sirolimus International Proficiency
TestingSchemesurvey,whichincludesthreemonthly
pooled blood samples from patients receiving siroli-
mus, or blood samples with added sirolimus. For 59
samples, the mean of the monthly overall laboratory
method means were 13.8910.99 mg/L (median 9.6
mg/L) for HPLC/UV and 12.9910.31 mg/L (median
9.3 mg/L) for MEIA. In our laboratory, the mean
sirolimus concentration obtained for the same 59
samples using the HPLC/UV assay was 12.499.67
mg/L (median 9.1 mg/L), and using MEIA 12.299.37
mg/L (median 9.0 mg/L). The correlation coefficients
obtained between our individual 59 results and the
overall laboratory method means were r 0.950 (PB
0.001) for HPLC, and r 0.965 (PB0.001) for
MEIA. The mean sirolimus concentration obtained
for these 59 interlaboratory quality control samples
using the FPIA assay was 12.899.36 mg/L (median
9.7mg/L).The Innofluor† FPIAassayhadpractically
a sirolimus cross-reactivity of 100%, significantly
greater thanthevalueof72%indicatedinthepackage
insert, with lower limits of detection and quantitation
respectively about 1.0 mg/L and 2.0 mg/L.
The within-run imprecision study was carried out
using the duplicates method, with blood samples
from liver and kidney transplant recipients assayed
twice for each of the methods, and with sirolimus
concentrations B5 mg/L, 5 10 mg/L and  10 mg/L.
Using the Innofluor† FPIA for 10 duplicates with a
mean sirolimus concentration of 3.890.25 mg/L, a
variation coefficient of 6.6% was obtained, for 41
duplicates with a mean concentration of 7.490.46
mg/L a variation coefficient of 6.3%, and for 13
duplicates with a mean concentration of 14.290.39
mg/L a variation coefficient of 2.7%. Using the MEIA
for 32 duplicates with a mean concentration of 3.59
0.20 mg/L a variation coefficient of 5.5% was
obtained, for 111 duplicates with a mean concentra-
tion of 7.690.28 mg/L avariation coefficient of 3.7%,
and for 51 duplicates with a mean concentration of
16.090.54 mg/L a variation coefficient of 3.4%.
Using the HPLC method for 40 duplicates with a
mean concentration of 3.890.34 mg/L a variation
coefficient of 9.0% was obtained, for 98 duplicates
with a mean concentration of 7.290.39 mg/L a
variation coefficient of 5.5%, and for 41 duplicates
with a mean concentration of 17.290.67 mg/L a
variation coefficient of 3.9%. Between-run impreci-
sion for the different methods was studied in the daily
quality control using the IMx† Sirolimus controls,
and the results are shown in Table I. For the FPIA
assay an analogous between-run imprecision was
obtained using the Innofluor† Certican† controls
(data not shown). In some cases, the obtained
variation coefficients were higher than the clinically
acceptable value of 6.3% according to previously
published criteria (21); however, in all cases these
variation coefficients (B15%) were acceptable in
accordance with the consensus recommendations for
the validation of analytical methods for determina-
tion of drugs and their metabolites (1,23).
The regression obtained between the MEIA and
HPLC results for the total number of samples
considered (Figure 1A) was in line with previously
published results (4 6,9,11,13). The differences
between the means (medians) obtained using the
FPIA, MEIA, and HPLC methods were lower than
the acceptable deviation error in accordance with the
considered validation criteria (1,21 23); however,
the standard errors of the estimates were slightly
higher than the clinically acceptable value (0.6 mg/L)
according to the considered criterion (21) as is
shown in Figure 1 (A, C, E). Similarly, the difference
plots (Figure 1B, D) show that a considerable
number of individual results provided by MEIA
and FPIA differ with respect to the HPLC (nominal)
values by more than 15%.
In the liver transplant recipients, the regression
and correlation between FPIA and HPLC results
were: FPIA 1.09 HPLC 0.57 (n 54, r 0.900,
ma68 1.0 mg/L), and in renal transplant patients:
FPIA 1.18 HPLC 0.04 (n 50, r 0.772,
ma68 0.95 mg/L). The relationship between
MEIA and HPLC in the liver transplant recipients
was: MEIA 1.08 HPLC 0.31 (n 62, r 0.925,
TableI.Between-runimprecisionstudyforsirolimusdetermination.
n Mean9SD (mg/L) CV (%)
Innofluor† FPIA
IMx† Sirolimus control L 30 5.4190.72 13.3
IMx† Sirolimus control M 30 10.5891.02 9.7
IMx† Sirolimus control H 30 21.0392.08 9.9
MEIA
IMx† Sirolimus control L 100 4.8090.41 8.6
IMx† Sirolimus control M 100 10.3090.69 6.7
IMx† Sirolimus control H 100 22.2891.56 7.0
HPLC
IMx† Sirolimus control L 22 4.9690.59 11.9
IMx† Sirolimus control M 22 11.0990.81 7.3
IMx† Sirolimus control H 22 22.5091.98 8.8
Assigned values: control L 5.0 mg/L; control M 11.0 mg/L;
control H 22.0 mg/L.
Determination of blood sirolimus concentrations 57ma68 0.77 mg/L), and in the renal recipients:
MEIA 1.24 HPLC   0.63 (n 84, r 0.764,
ma68 0.90 mg/L). The regression and correlation
obtained between the FPIA and MEIA in the liver
transplant recipients were: FPIA 1.00 MEIA 
0.37 (n 54, r 0.964, ma68 0.72 mg/L), and in
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Figure 1. Correlation and regression (A, C, E) and difference plots (B, D, F) for sirolimus concentrations using the MEIA, FPIA, and
HPLC in blood samples from liver (k) and kidney (m) transplant recipient patients. The dotted lines correspond to the limits of the
acceptance criterion for deviation.
58 L. Bouzas et al.the renal transplant recipients: FPIA 1.04 MEIA  
0.21 (n 52, r 0.849, ma68 0.70 mg/L).
The group of liver transplant patients had
significantly higher levels of GFR (PB0.001), and
bilirubin (PB0.05), and significantly lower levels of
albumin (PB0.001), than the group of renal trans-
plant patients. As shown in Table II, no significant
differences were found between both groups of
patients for sirolimus CL, and the FPIA/HPLC,
MEIA/HPLC, and FPIA/MEIA sirolimus concen-
tration ratios. The interindividual variation for
sirolimus CL was greater in the group of liver
transplant recipients (CV 74%), than in the kidney
transplant recipients group (CV 40%). Possible
pharmacokinetic interactions due to the concomi-
tant administration in some cases of enzyme-indu-
cing or -inhibiting drugs were not considered.
A significant negative correlation was found for
sirolimus CL with the sirolimus concentration in the
total patient group (r  0.589, PB0.001), kidney
transplant patients (r  0.292, PB0.05), and liver
transplant patients (r  0.859, PB0.001). Signifi-
cant positive correlations were also found for the
FPIA/HPLC and MEIA/HPLC sirolimus concen-
tration ratios with sirolimus CL in the total patient
group (PB0.01) and liver transplant patient group
(PB0.005); however, in the first-order partial cor-
relation, keeping the sirolimus concentration con-
stant, no statistical significance was achieved
between these variables. Neither were any significant
correlations found in the total patient group for the
FPIA/HPLC, MEIA/HPLC, and FPIA/MEIA siro-
limus concentration ratios with the estimated GFR
(range 19.8 125.3 mL/min/1.73 m
2), blood hema-
tocrit (range 20.7% 48.5%), albumin (range 1.5 
4.4 g/dL), or bilirubin (range 0.1 2.2 mg/dL).
Discussion
The results obtained in the imprecision study for
FPIA, MEIA, and HPLC may be considered satis-
factory. Although the variation coefficients in some
cases were higher than the clinically acceptable value
of 6.3% (21), the acceptance limit of 15% (23,24)
was not exceeded in any case. The FPIA imprecision
was in general slightly greater than that given by the
MEIA assay, and this fact may be due to the FPIA
procedure for preparing blood samples, which re-
quires methanol extraction prior to the addition of
the precipitation reagent, whereas MEIA uses a
simpler procedure with only one extraction/precipi-
tation reagent.
Although some authors have found similar re-
sults using MEIA and HPLC (7,8,10,12), it is
generally accepted that the MEIA leads to an over-
estimation of the sirolimus concentration in patients’
samples, related to the antibody reacting with
hydroxyl- and desmethyl-sirolimus metabolites (4 
6,9,11,13,25). The FPIA and MEIA assays provided
similar results, with a high correlation coefficient
between them, and a standard error of the estimate
only slightly higher than the acceptable value (Figure
1E). Likewise, as shown in Figure 1, both immu-
noassays tend to overestimate the concentrations of
sirolimus with respect to the values obtained by
HPLC; however, the difference between the means
(medians) obtained is acceptable in accordance with
the validation criteria considered (1,21 23). Higher
correlation coefficients between the different meth-
ods were obtained in the group of liver transplant
patients than in the group of kidney transplant
patients, although the lower range of sirolimus
concentrations in this patient group may be con-
sidered a contributing factor to this result.
It has been indicated that other variables, such as
the time after kidney transplantation (25) and blood
hematocrit (4,25), may be significant in the over-
estimation of sirolimus by MEIA; however, for other
authors these factors do not have any influence on
the overestimation of sirolimus using the MEIA
assay (6). In our study, it was not possible to confirm
the possible interference effect of the hematocrit
(range 20.7% 48.5%) on either of the immunoas-
says used, as statistical significance was not achieved
in the correlation of the FPIA/HPLC, MEIA/HPLC,
and FPIA/MEIA sirolimus concentration ratios with
the hematocrit. Similarly, no significant correlations
were found between the sirolimus concentration
ratios and the estimated GFR, or the serum levels
of albumin and bilirubin.
Variations in sirolimus absorption and clearance
result in a wide range of trough concentrations
among patients receiving the same dose. Although
in hepatic dysfunction the intestinal absorption of
sirolimus may not be significantly affected, patients
with liver disease showed decreased sirolimus CL
(26,27), and increased concentrations of the parent
drug and its metabolites (3); however, a considerable
overlap in sirolimus CL among healthy subjects and
Table II. Sirolimus clearance (CL) and sirolimus concentration
ratios in liver and kidney transplant recipients.
Liver transplant
(n 54)
Kidney transplant
(n 50)
Sirolimus CL (L/h)
a 3.7092.73 (2.61) 3.4691.37 (3.19)
FPIA/HPLC ratio 1.2190.36 (1.18) 1.1990.21 (1.19)
MEIA/HPLC ratio 1.1490.23 (1.14) 1.1890.18 (1.15)
FPIA/MEIA ratio 1.0390.14 (1.06) 1.0390.14 (1.02)
aCalculated from Css determined by HPLC.
Determination of blood sirolimus concentrations 59patients with mild, moderate, or severe hepatic
impairment was previously described (26,27). In
our study, a large overlap was also found between the
values of sirolimus CL for the groups of patients
with liver and kidney transplants, without any
significant difference for this pharmacokinetic vari-
able between both groups. Neither were any sig-
nificant differences found between these groups of
patients for the FPIA/HPLC, MEIA/HPLC, and
FPIA/MEIA sirolimus concentration ratios, nor any
significant first-order partial correlations for these
concentration ratios with sirolimus CL. These re-
sults are the opposite to those that would be
expected, and suggest that the sirolimus metaboliza-
tion rate does not appear to be capable of introdu-
cing an additional source for the FPIA and MEIA
deviation with respect to the HPLC results, whose
clinical significance is mainly conditioned by the
relative proportions of sirolimus and its metabolites
in the blood samples.
The sirolimus-metabolite cross-reactivity with
the MEIA antibody could lead to a variable bias
with respect to HPLC results; however, this immu-
noassay is widely used for routine sirolimus deter-
mination, with MEIA users currently representing
39% of the total participants in the Sirolimus
International Proficiency Testing Scheme survey.
In accordance with our results (Figure 1F), a higher
cross-reactivity of the Innofluor† FPIA for lower
sirolimus concentrations than 5 mg/L has been
previously described (28); however, a correction of
the results appears unnecessary in the routine
practice, and the FPIA assay may be a valid
alternative to the MEIA with analogous performance
for the therapeutic monitoring of sirolimus.
We have previously described that everolimus
may be quantified using the Sirolimus MEIA assay
(29), and consequently sirolimus and everolimus
determination may be carried out using a common
FPIA or MEIA assay, which would reduce the
reagent costs. The choice of the Innofluor†
Certican† FPIA or the Sirolimus MEIA for the
determination of both immunosuppressive agents
may be made on the basis of the TDx and IMx
analyser availability.
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